Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China-Reference-Cited by-同舟云学术

Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China

Published:2021-02-14 Issue:9 Volume:147 Page:2701-2708
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Sun Yu,Zheng Yuzhu,Yang Xiaoyun,Xie Ke,Du Chi,He Lang,Gui Yan,Fu Jiangping,Li Changlin,Zhang Huiling,Zhu Li,Bie Jun,Sun Yi,Fu Yu,Zhou Yangang,Shou Feng,Wang Yan,Zhu Jiang^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-021-03554-1.pdf

Reference15 articles.

1. Aapro M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986–1992. https://doi.org/10.1093/annonc/mds021

2. Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20:141–147. https://doi.org/10.1007/s00520-010-1079-3

3. Clark-Snow R, Affronti ML, Rittenberg CN (2018) Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer 26:557–564. https://doi.org/10.1007/s00520-017-3866-6

4. Hatoum HT, Lin SJ, Buchner D, Cox D (2012) Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice. Support Care Cancer 20:941–949. https://doi.org/10.1007/s00520-011-1165-1

5. Hu Z et al (2014) Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. Support Care Cancer 22:979–987. https://doi.org/10.1007/s00520-013-2043-9

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting;Journal of Cancer Research and Clinical Oncology;2024-06-05

2. A nurse-led multidomain intervention to improve the management of chemotherapy-induced nausea and vomiting in patients with head and neck cancers: A randomized controlled trial;European Journal of Oncology Nursing;2024-06

3. Characteristics of nausea and its impact on health-related quality of life in cisplatin-treated patients receiving dexamethasone-sparing prophylaxis: an analysis of the LUNG-NEPA study;Supportive Care in Cancer;2024-03

4. Oral compound probiotic supplements can improve the quality of life for patients with lung cancer during chemotherapy: A randomized placebo‐controlled study;Thoracic Cancer;2023-11-29

5. Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy;Expert Opinion on Pharmacotherapy;2023-11-27